Evidence map›Paper›PMID 31413098›Full record

ArticleHaematologica2020

Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms.

Kaitlyn Shank, Andrew Dunbar, Priya Koppikar, Maria Kleppe, Julie Teruya-Feldstein, Isabelle Csete, Neha Bhagwat, Matthew Keller, Outi Kilpivaara, Franziska Michor and 2 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kaitlyn ShankHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Andrew DunbarHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Priya KoppikarHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Maria KleppeHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Julie Teruya-FeldsteinDepartment of Pathology, Icahn School of Medicine, Mount Sinai, New York, NY, USA.
Isabelle CseteHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Neha BhagwatHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Matthew KellerHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Outi KilpivaaraHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Franziska MichorDepartment of Biostatistics and Computational Biology, Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA, USA.
Ross L LevineHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Laura de Vargas RoditiInstitute of Molecular Cancer Research, University of Zurich, Zurich Switzerland laura.devargasroditi@uzh.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Janus Kinase InhibitorsMyeloproliferative DisordersNeoplasmsHumansJanus Kinase 2Models, TheoreticalProtein Kinase InhibitorsJanus Kinase 2Janus Kinase InhibitorsProtein Kinase Inhibitors

Identifiers

PMID31413098
PMCPMC7049364

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.